profit from every $100 of sales.
$0$100
Zentek
We have no price for Zentek since 1 September 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$0.49-5.02% today
-37.8% since Oct 8, 25
1-year low $0.371-year high $1.06
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Zentek sold, what it kept, and what it did with the cash.
Sales went from $339,666 in 2022 to $872,495 in 2025, with -$10.0 million of profit last year.
SalesProfit
Zentek vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Zentek | No profit yet | ||
 ResMed | 22.0× · Fair price | ||
 West Pharmaceutical Services | 58.3× · Expensive | ||
 Hologic | 30.0× · Fair price | ||
 Baxter International | No profit yet |
AI analysis
An AI analyst reads Zentek's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 1 | |
| -0 | -1 | -0 | 0 | |
| -12 | -15 | -12 | -10 | |
| -31 | -14 | -11 | -9 | |
| -32 | -14 | -12 | -10 | |
| -0.34 | -0.14 | -0.12 | -0.10 | |
| -10.9% | -1,071.3% | -1,010.4% | 22.1% | |
| -3,528.5% | -20,112.5% | -40,174.8% | -1,100.4% | |
| -9,330.9% | -19,784.9% | -39,254.1% | -1,150.7% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 45 | 33 | 23 | 18 |
| Cash | 27 | 10 | 4 | 0 |
| Total debt | 2 | 2 | 1 | 1 |
| Total liabilities | 3 | 3 | 2 | 4 |
| 42 | 30 | 20 | 15 | |
| 92 | 99 | 101 | 103 | |
| -57.1% | -35.3% | -43.1% | -50.9% | |
| -76.3% | -47.4% | -58.0% | -68.1% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -8 | -13 | -8 | -6 | |
| 4 | 2 | 1 | 0 | |
| -12 | -15 | -9 | -6 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 5 | 3 | 2 | 2 |
Valuation
- –
- –
- –
- 9.7×
- 71.4×
- –
- –
- -10.4%
- -16.1%
- 0.0%
Profitability
- 22.1%
- -1,100.4%
- -1,150.7%
- -833.3%
- -61.5%
- -57.6%
- -61.3%
- -46.5%
- -62.3%
- 143.9%
Growth
- +37.0%
- –
- −1.7%
- –
- +5.2%
Financial health
- –
- 0.15
- 10.9%
- -46.6×
- 1.00
- 0.74
- 0.05
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 4%of 958
Top 15%of 889
Bottom 10%of 987
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Feb 17, 2026 | -0.01 | -0.02 | +58.3% |
| Nov 13, 2025 | -0.02 | – | – |
| Aug 14, 2025 | -0.01 | – | – |
| Jun 26, 2025 | -0.01 | – | – |
| Feb 12, 2025 | -0.01 | – | – |
| Nov 13, 2024 | -0.02 | – | – |
| Jun 26, 2024 | -0.02 | -0.01 | −171.0% |
| Feb 12, 2024 | -0.02 | -0.02 | −32.5% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
16No pass
Benjamin Graham
23No pass
Philip Fisher
32No pass
Peter Lynch
98Pass
Joel Greenblatt
0No pass
Charlie Munger
20No pass
Terry Smith
15No pass
Questions about Zentek
Is Zentek a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Zentek AI analysis
What does Zentek do?
Zentek Ltd. engages in the research and development of graphene and related nanomaterials in Canada. It owns 100% interest in the Albany Graphite project located in Northern Ontario, Canada. It is in Medical - Instruments & Supplies.
Does Zentek pay a dividend?
No. Zentek does not pay a dividend at the moment.
Is Zentek stock halal?
Yes. Zentek passes our halal screen: its business is permitted and its debt is 1% of its market value, under the 30% limit. How we check
Who are Zentek's competitors?
The largest listed companies in the same industry are ResMed, West Pharmaceutical Services, Hologic and Baxter International. The peers table on this page compares their profit, growth and price with Zentek's.
Prices: daily closes to Sep 1, 2026. Fundamentals: company reports via invest-like data.